NCT02361645View on ClinicalTrials.gov

NSAIDs and PGE2 Levels in Vitrectomy Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

January 31, 2015

Conditions
Vitreous Inflammation
Interventions
DRUG

Ketorolac 0.5% eyedrops

DRUG

Indomethacin 0.5% eyedrops

DRUG

Bromfenac 0.09% eyedrops

DRUG

Nepafenac 0.1% eyedrops

All Listed Sponsors
lead

Università degli Studi di Brescia

OTHER

NCT02361645 - NSAIDs and PGE2 Levels in Vitrectomy Patients | Biotech Hunter | Biotech Hunter